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BSA Bovin serum albumin 
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GI/TGF-B BSC-1 cell-derived growth inhibitor 
PDGF Platelet-derived growth factor 
MEP Major excreted protein 
MRP Mitogen-regulated protein 
Platelet TGF-B Human platelet transforming growth factor-6 
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GENERAL INTRODUCTION 
Growth is a fundamental process of all living organisms. The 
growth and metabolic activity of mammalian cells is regulated by growth 
factors and other hormones. Growth factors are a class of hormones 
which have the following characteristics: (1) they are polypeptides (2) 
they act from outside the cell to initiate a cellular response (3) they 
initiate cellular responses exclusively by the formation of specific 
growth factor receptor complexes, that mediate a specific hypertrophic 
and/or hyperplastic response, (4) they and their receptors are removed 
from the cell surface by receptor-mediated endocytosis for the minimal 
purpose of degradation or receptor recycling (1). 
The common effect of growth factors is to stimulate DNA synthesis 
and mitosis of receptive cells. The tissue sources of growth factors 
are diverse, probably reflecting the existence of many different 
delivery systems for carrying each factor to its appropriate target 
cells in vivo. The sources include plasma, clotted blood serum, 
platelets, submaxillary glands, pituitary gland, brain, kidney, normal 
cells, virally-transformed cells, malignant cells in culture, and their 
conditioned medium. The well-characterized growth factors include 
epidermal growth factor (EGF), fibroblast growth factor (FGF), 
transforming growth factor (TGF-a & TGF-B), platelet-derived growth 
factor (PDGF), insulin-like growth factor (IGF-I & IGF-II), and nerve 
growth factor (NGF). Because most of my work was done with EGF, FGF and 
TGF-B, these three growth factors will be discussed in more detail. 
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Epidermal growth factor (EGF) was first identified by S. Cohen (2, 
3) from mouse submaxillary gland. It is an acidic (pi 4.6), single 
chain polypeptide composed of 53 amino acids with three disulfide bonds 
and a molecular weight of 6045 (4, 5). An homologous protein, human 
urogastrcne, has been isolated from human urine (6). EGF exhibits 
multiple effects in vivo and in vitro. Extracts of mouse submaxillary 
glands injected into newborn animals induce precocious eyelid opening 
and incisor eruption (2, 3) due to the stimulation of epidermal growth 
and keratinization (7, 8). Other effects of EGF in vivo include the 
proliferation of skin tissue (8), corneal (9, 10), lung, and tracheal 
epithelia (11, 12), inhibition of gastric secretion (13, 14), and 
potentiation of cleft palate (15, 16). In cell culture, EGF stimulates 
proliferation in a variety of cells such as mammary epithelial cells 
(17), mouse and human fibroblasts (18, 19, 20), glial cells (21), 
keratinocytes (22), bovine granulosa cells (23), rat hepatocytes (24), 
vascular endothelial cell (25), corneal endothelial cells (26), and 
rabbit chondrocytes (27). EGF also stimulates ion and nutrient 
transportation (28, 29, 30, 31), enhances the phosphorylation of 
endogenous membrane proteins (32) and of the ribosomal protein S6 (33), 
induces the specific changes in the organization of the cytoskeleton 
(34), causes changes in cell morphology (35), and increases the 
biosynthesis of fibronectin (36), keratin (22), and the enzyme ornithine 
decarboxylase (37). 
Fibroblast growth factor (FGF) was first purified by D. 
Gospodarowicz (38, 39, 40, 41) from both pituitary and brain tissue. 
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Both FGFs are heat-labile basic polypeptides (pi 9.2-9.6) with molecular 
weight of 13,000. Brain FGF has been shown to be an angiogenic factor 
in vivo (41) and to stimulate the proliferation of blastemal cells in 
frog and could therefore contribute to the regeneration process in lower 
vertebrates (42, 43, 44, 45). FGF stimulates the growth of a variety of 
cells in culture including mouse and human fibroblasts (46, 47), human 
glial cells (48), aortic smooth muscle cells (49), chondrocytes (50, 
51), and endothelial cells (51). In addition to its mitogenic effects, 
FGF stimulates the transport of amino acid, nucleotides, and 
carbohydrates, and promotes protein and RNA synthesis (51, 52, 53). 
Transforming growth factors (TGFs) were first identified as sarcoma 
growth factors (SGFs) by De Larco and Todaro (54, 55) from the 
conditioned medium of murine sarcoma virus-transformed fibroblasts. 
TGFs are a new class of growth factor which is able to reversibly induce 
nonneoplastic cells to express the transformed phenotype. The 
transformed phenotype is characterized by the loss of density-dependent 
inhibition of growth in monolayer and by the acquisition of anchorage-
independent growth. A variety of sources of TGFs have been found, 
including conditioned media from nonneoplastic (56, 57) and transformed 
cell cultures (54, 58, 59), neoplastic cells or tissues (60, 61, 62, 
63), nonneoplastic cells or tissues (61, 64, 65, 66), human platelets 
(67), and fetal calf serum (68). There are two types of TGFs that can 
be distinguished according to their ability to bind to the EGF receptor. 
Type Q TGF (Mp 5,700) shares sequence homology with EGF and binds to the 
EGF receptor (55, 69, 70, 71, 72, 73). Type g TGF (% 25,000) has a 
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different amino acid sequence from TGF-a and binds to a receptor 
distinct from the EGF receptor (65, 66, 67, 74, 75). Growth inhibitor 
(GI/TGF-B) is a protein isolated from the conditioned medium of African 
green monkey epithelial BSC-1 cells (76). TGF-6 from human platelets 
and GI/TGF-B from BSC-1 cell have been suggested to be the same or 
closely related molecules (75). They both stimulate colony formation in 
soft agar and compete with each other for binding to AKR-2B cells. TGF-
B and GI/TGF-B also have the same molecular weight and subunit 
compositions and are able to inhibit DNA synthesis in BSC-1 and CCL-64 
cells. TGFs are versatile and their functions are diverse. They 
accelerate experimental wound healing in vivo (77, 78). In vitro, TGFs 
stimulate bone resorption (79), glycolysis and amino acid uptake (80), 
inhibit DNA synthesis (75, 76, 81, 82, Thalacker and Nilsen-Hamilton, 
manuscript in preparation, department of Biochemistry and Biophysics, 
ISU), and stimulate cell growth in soft agar or monolayer (83). 
A tumor promoter is an agent that enhances tumor formation in 
animals treated with a carcinogen. The first tumor promoter, 12-0-
tetradecanoylphorbol 13-acetate (TPA), was isolated from croton oil 
derived from the seed of the plant Croton tiglium (84). TPA is still 
the most potent phorbol ester tumor promoter known and it is widely used 
in vivo and in vitro. TPA exerts its effects through a specific 
receptor, protein kinase C (85, 86, 87, 88). In some cells, tumor 
promoter mimicks the effects of growth factors by stimulating DNA 
synthesis and cell proliferation (89), inducing the production of 
collagenase and plasminogen activator (90, 91, 92), and increasing 
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prostaglandin synthesis (93, 94). It has been suggested that the reason 
for the similar biological action of TPA and growth factors is that they 
act through a common intermediate-protein kinase C (85, 86, 95). 
Intercellular communication via regulatory chemical messengers had 
been proposed to occur through three different mechanisms, endocrine, 
paracrine, and autocrine (96, 97, 98). The typical example of endocrine 
regulation is the hormones which are transported by blood vessels to 
their target cells. Intercellular communication that involves growth 
factors is usually between neighboring cells. This is paracrine 
regulation. Some types of cells release polypeptide growth factors such 
as TGF-a and TGF-B into conditioned medium when they grow in cell 
culture. They respond to these same polypeptides via external receptors 
on their own cell surfaces (54, 55, 56, 57, 61, 62, 64, 76). This 
process has been termed "Autocrine Secretion" by Spom and Todaro (97). 
Endocrine hormones and paracrine and autocrine growth factors are 
believed to regulate normal growth and development in vivo (77, 78). 
It has been reported that the cell cycle of the cells can be 
regulated by growth factors in vitro (1, 99, 100, 101, 102, 103). The 
cell cycle is composed of four successive phases - M, Gi, S, and Gz. 
The M phase is the period during which cell-division occurs and S phase 
is the only time in the cell cycle during which nuclear DNA is 
replicated. The differences in cell cycle times measured for different 
cells are due mainly to variations in the length of Gi. Quiescent 
(growth-arrested) cells are believed to be arrested in a specific 
subphase of the cell cycle termed the Go phase that is not part of the 
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main cell cycle (99, 100). It has been proposed that quiescent cells 
progress from Go to S in two stages. First the cells become competent, 
then they progress through Gi to S. In the model, when quiescent cells 
are capable of being stimulated to progress through the S phase, they 
are refered to as being in the competent state which is at the Go and Gi 
border (100). According to their mitogenic action on Balb/c 3T3 cells, 
growth factors have been divided into two groups (100, 101, 102). The 
first group of growth factors have been called competence factors -
these include PDGF and FGF. Competence factors induce cells to shift 
from the arrested state to competent state in the cell cycle. The 
second group of growth factors have been called progression factors, and 
include EGF and IGF. Progression factors stimulate the progress of 
cells from the competent state to DNA synthesis. However, this model 
may not apply to all cell types. Some workers have noted that for human 
glial cells competence factors may only require proper tissue culture 
conditions to act in a progressive manner (103). 
Protein synthesis is central to cell growth, development, and 
maintenance. Proteins are found to be synthesized on ribosomes attached 
to endoplasmic reticulum (EIR). As it is synthesized the protein passes 
through the membrane into the lumen of ER, the protein then moves from 
the ER to the Golgi apparatus. Once in the lumen of the Golgi 
apparatus, these proteins are covalently modified in a variety of way to 
produce their final mature forms. Then these mature proteins are sorted 
to different intracellular and extracellular destinations from the Golgi 
apparatus. Proteins destined for secretion are packaged into Golgi-
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derived secretory vesicles that then fuse with the plasma membrane. 
Primary lysosomes are formed by budding from the Golgi apparatus. 
Lysosomes are the principal sites of intracellular digestion. The 
concentration of a protein in a cell is determined by the balance 
between the rate of synthesis and the rate of degradation. The rate of 
synthesis is usually controlled by regulating the amount of mRNA 
available for translation. In addition, a cell can control the 
concentration of a protein by regulating the rate at which the protein 
is degraded. 
The intracellular level of a secreted protein is also regulated by 
the process of secretion. Many proteins are secreted by cells, 
including growth factors, growth inhibitors, extracellular matrix 
proteins, proteases, and protease inhibitors. Thus protein secretion is 
an important physiological characteristic that influences cell 
morphology, proliferation, differentiation, communication, movement, and 
transformation. It had been shown that growth factors and tumor 
promoters regulated the amount of several proteins secreted by 
fibroblasts and other cell types such as collagenase (104, 105, 106, 
107), collagenase inhibitor (108), plasminogen activator (87, 109, 110), 
collagen (111, 112), fibronectin (112), hCG (113, 114), somatomedin C 
(115), and lymphokines (116) by different types of cells. Our lab has 
reported that mitogens regulate the secreted levels of Mitogen Regulated 
Protein (MRP), Major Excreted Protein (MEP) (117, 118, 119, 120, 121, 
122, Chiang et al., manuscript in preparation, departments of Zoology 
and Biochemistry and Biophysics, ISU), Superinducible Proteins (SIPs) 
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(123), Growth Inhibitor Induced Protein (IIP) (124, Thalacker and 
Nilsen-Hamilton, manuscript in preparation), and Mitogen Induced 
Proteins (MIPs), MIP59 and MIP62 (124), and MIP52 (122, Chiang et al., 
manuscript in preparation, departments of Zoology and Biochemistry and 
Biophysics, ISU). The production of MRP and MEP are also increased by 
tumor promoters (Fienup et al., publication submitted, department of 
Biochemistry and Biophysics, ISU) and lysosomotropic agents (118). 
MRP (Mj. 34,000) is a heterogeneously glycosylated protein secreted 
by Swiss 3T3 cells (117). It has been reported that MRP has 32% 
sequence homology with prolactin (125). MRP is identical to proliferin 
which was discovered through its cDNA clone by Linzer and Nathans (126). 
MEP (Mp 39,000) is a glycosylated thiol protease located intracellularly 
in the lysosomes and secreted by both Balb/c and Swiss 3T3 cells (117, 
127, 128). Growth factors and tumor promoters increase both 
intracellular and secreted MRP and MEP (117, 118, 119, 120, 121, 122, 
129, Fienup et al., manuscript submitted, Chiang et al., manuscript in 
preparation). This increase in intracellular MRP and MEP is due to an 
increase in MRP and MEP mRNA levels (125, 129, 130, 131). Growth 
factors and TPA also stimulate human fibroblasts to produce a 52 kDa 
Mitogen-Induced Protein (MIP52) (Chiang et al., manuscript in 
preparation). 
The growth and metabolic activity of a single cell type is 
regulated by more than one growth factor. Studies of the cellular 
responses to combinations of several growth factors show that the 
pathways through which these growth factors regulate cellular function 
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must interact. The interaction of growth regulators can act in the 
their effect on DNA synthesis. For example it has been shown that TGF-6 
has a faiphasic effect on EGF-stimulated thymidine incorporation; it 
exerted a transient decrease followed by a prolonged increase in 
EGF-specific thymidine incorporation in NRK cells (132). Also, the 
inhibitory effect of GI/TGF-B on DNA synthesis was counteracted by EGF 
or calf serum in BSC-1 cells (76). The interaction between growth 
regulators can also result in changes in gene expression (134, 135, 136, 
137), the levels of receptors (72, 138, 139), and/or the levels of 
common intermediates (75, 134, 140, 141). 
The variety of source and diverse effects of TGF-6 suggest that it 
maybe play an important physiological role in cells. The mechanisms 
by which TGF-B exerts its cellular responses are still not clear. In 
this thesis, I investigated the effects of TGF-B, EGF, F6F, TPA and 
their interaction on the production of secreted proteins by mouse 3T3 
cells and human fibroblasts. The major mechanism through which TGF-6 
and EGF regulate MRP production was also studied. Finally, the 
influence of the growth state of the cells on the ability of TGF-B, EGF, 
FGF, and TPA to regulate the production of MRP, MEP, and MIP52 was 
investigated. 
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Elxplanation of Dissertation Format 
An alternative format was used in this dissertation. There are 
three sections after the General Introduction, each of the sections is 
an individual paper. The first section is in Press in Journal of 
Biological Chemistry, the other two sections will be submitted for 
publication. Finally, a general discussion and summary of the 
dissertation is included. In the first two sections, the experiments 
were performed entirely by myself. In the last section, the 
experimental work was done mostly by myself and some by Dr. Marit 
Nilsen-Hamilton. These three manuscripts were prepared by myself with 
assistance from my major professor. Dr. Marit Nilsen-Hamilton, in 
editing and revision. 
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SECTION I: 
OPPOSITE AND SELECTIVE EFFECTS OF EGF AND TGF-6 
ON THE PRODUCTION OF SECRETED PROTEINS BY 
MURINE 3T3 CELLS AND HUMAN FIBROBLASTS 
Chia-Ping Chiang^ and Marit Nilsen-Hamilton^ 
Departments of Zoology^ and Biochemistry and Biophysics^ 
Iowa State University 
Ames, Iowa 50011 
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ABSTRACT 
Growth regulators such as epidermal growth factor (EGF) and type g 
transforming growth factor (TGF-6) regulate the synthesis and secretion 
of certain proteins by cells in culture. The secretion pattern of each 
cell line and the effect of growth regulators on the secretion pattern 
are unique. EGF increased the secreted and intracellular levels of 
Mitogen-Regulated Protein (MRP) and Major Excreted Protein (MEP) by 
Swiss 3T3 cells. MRP is related by sequence to prolactin. MEP is a 
thiol protease located intracellularly in the lysosomes. EGF also 
selectively induced a 52,000-dalton Mitogen-Induced Protein (MIP 52) 
secreted by human fibroblasts. Two types of TGF-6s were tested for 
their effects on the expression of secreted proteins in mouse and human 
fibroblasts : TGF-6 from human platelets and a growth inhibitor (GI/TGF-
S) secreted by BSC-1 cells. Each selectively decreased the levels of 
the two secreted proteins induced by growth factors in mouse embryo 3T3 
cells and one secreted protein induced by growth factors in human 
fibroblasts. Platelet TGF-6 and GI/TGF-6 also induced one 48,000-dalton 
protein secreted by human fibroblasts. Synthesis of DNA and the 
incorporation of [^^Slmethionine into total protein in Swiss 3T3 cells 
were not affected by platelet TGF-6 or GI/TGF-6. Thus the inhibitory 
effect of platelet TGF-6 on the synthesis and secretion of these three 
proteins is due to a specific effect of platelet TGF-6 on the regulation 
of MRP and MEP that does not interfere with the ability of EGF to 
stimulate DNA or protein synthesis. 
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INTRODUCTION 
Transforming growth factors (TGFs) are small proteins that induce 
nonneoplastic cells to lose density-dependent inhibition of 
proliferation and grow independently of anchorage (1, 2, 3, 4). Two 
types of TGF have been identified and isolated from a wide variety, of 
sources which include virally and chemically transformed cells grown in 
vivo, neoplastic and nonneoplastic tissues, and human and bovine 
platelets (2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14). TGF type a (Mj- 5,700) 
shares sequence homology with epidermal growth factor (EGF) and binds to 
the EGF receptor (15, 16, 17, 18, 19). TGF type 8 (M^ 25,000) has a 
different amino acid sequence from TGF-a and binds to a receptor 
distinct from the EGF receptor (4, 6, 10, 20, 21). TGF-6 from human 
platelets and the growth inhibitor (GI/TGF-B) from BSC-1 African green 
monkey kidney epithelial cells are the same or closely related molecules 
(22). Platelet TGF-6 and GI/TGF-6 compete with each other for binding 
to AKR-2B cells. They each stimulate colony formation in soft agar and 
inhibit DNA synthesis and the division of several types of cells in 
monolayer culture. Platelet TGF-g and GI/TGF-6 also have the same 
molecular weights and subunit compositions. 
One dramatic effect of polypeptide growth factors on cells in 
culture is the selective induction of certain secreted proteins. 
Induction has been shown for fibroblast and epithelial cell lines from 
human, monkey, rat, and mouse (23, 24, 25, 26, 27, 28). The secretion 
pattern of each cell line is unique, and so is the effect of the growth 
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factors on the secretion pattern. Fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF), EGF, and serum selectively 
stimulate Swiss 3T3 cells to synthesize Mitogen-Regulated Protein (MRP) 
and Major Elxcreted Protein (MEP) (23, 29, 30, 31). MRP is a heavily 
glycosylated 34 kDa protein related to prolactin (23, 29, 30). MEP is a 
39 kDa secreted lysosomal glycoprotein (31, 32, 33). In this report, we 
show that platelet TGF-B and GI/TGF-6 selectively reduced both secreted 
and intracellular levels of MRP and MEP but did not affect DMA synthesis 
stimulated by EGF in 3T3 cells. We found the same opposing actions of 
EGF and platelet TGF-B in regulating the levels of the EGF-induced 
secreted protein Mitogen-Induced Protein 52 (MIP 52) secreted by human 
fibroblasts. Our results suggest that platelet TGF-6 does not decrease 
the secreted levels of EGF-induced proteins by reducing the ability of 
the EGF receptor to activate cellular functions. Thus TGF-6 selectively 
decreases the expression of MRP, MEP, and MIP 52 by a mechanism that 
does not interfere with the initiation of DNA synthesis. 
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MATERIALS' AND METHODS 
Murine EGF was purchased from Collaborative Research. Crystalline 
bovine insulin was obtained from Eli Lilly. Type B TGF purified from 
human platelet was a gift from Harold. L. Moses (Mayo Clinic, Rochester, 
MN. ). BSC-1 Growth Inhibitor was a gift from Robert. W. Holley (Salk 
Institute, San Diego, CA.). [^^S]methionine (1195-1500 Ci/iranole) and 
[^H]thymidine (51 Ci/mmole) were purchased from Amersham-Searle. The 
[^^S]methionine was stored in liquid nitrogen. Antibodies to purified 
MRP and MEP were made in rabbits (Nilsen-Hamilton et al., submitted for 
publication). 
Stock cultures of Swiss 3T3 cells were grown in Dulbecco-Vogt* s 
modified Eagle's medium (DME) supplemented with 10% calf serum and 
maintained at 37°C in a water-saturated atmosphere of 13% CO2, 87% air. 
Human fibroblasts were cultured in DME with 10% fetal calf serum. The 
cultures were checked for mycoplasma by autoradiography of 
[^H]thymidine-labeled cultures. No mycoplasma were found. 
The amount of [^®S]methionine incorporated into specific proteins 
released into the extracellular medium and in cell fractions were 
measured as described by Nilsen-Hamilton et al. (23). Swiss 3T3 cells 
were plated on multiwell plastic dishes with 10% calf serum and grown 
until they were confluent. Then the medium was changed to fresh DME 
containing 2% calf serum for 2-3 days. Sixteen to eighteen hours after 
the mitogens were added to the conditioned medium, the cells were 
labeled with [^®S]methionine for 4 h as described previously (23). The 
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EGF stocks were dissolved in 0.5% BSA and platelet TGF-B in 0.5 M acetic 
acid. Therefore the final concentration in each well, including the 
control wells, was 0.005% BSA and 1.7 mM acetic acid. Human fibroblasts 
were treated in the same way as the 3T3 cells except that the cells were 
cultured in DME with 10% fetal calf serum, and [^^S]methionine labeling 
was done 24 h after addition of EGF or TGF-6. 
[^^S]methionine-labeled postnuclear supernatant or medium samples 
were immunoprecipitated with anti-MRP and anti-MEP antisera, each 
antiserum at a final concentration of 1%. After preabsorption with 1% 
normal rabbit serum and 6.7 ug/ul killed Staphylococcus aureus, the 
antiserum and samples were incubated at 4°C for 2 h with 10.3 ug/ul 
killed S, aureus and immunoprecipitation buffer (0.15 M NaCl, 0.1% SDS, 
1% NP40, 1% sodium deoxycholate, and 10 mM NaPi, pH 7.2). 
Immunoprecipitates were collected by centrifugation and washed three 
times with immunoprecipitation buffer. The samples were resuspended in 
electrophoresis buffer to give a final concentrations of 2% (w/v) SDS, 
2% (v/v) S-mercaptoethanol, 10% glycerol, 0.004% bromophenol blue, and 
59 mM Tris-POi, (pH 6.9). Then they were resolved by SDS polyacrylamide 
gel electrophoresis. Fluorograms of PPO-impregnated SDS polyacrylamide 
gels were scanned with a densitometer (23). 
To determine the amount of [^®S]methionine incorporated.into 
cellular proteins, the labeled proteins in the postnuclear supernatant 
were precipitated with cold 10% TCA for 30 rain. The precipitates were 
trapped on glass fiber filters and washed with 15 ml cold 10% TCA then 2 
ml 95% ethanol. The amount of incorporated [^^S]methionine was measured 
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using a liquid scintillation spectrometer. 
Incorporation [^H]thymidine into cells grown on glass or plastic 
coverslips was measured as described previously (23). 
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RESULTS 
The amount of [^®S3methionine incorporated into MRP and MEP 
secreted by Swiss 3T3 cells was selectively increased by EGF, whereas it 
was appreciably reduced by platelet TGF-6 (Fig. lA). GI/TGF-B had the 
same inhibitory effect as platelet TGF-6 on the incorporation of 
C^®S]methionine into secreted MRP and MEP (Fig. lA). After 
inununoprecipitating MRP and MEP from samples of postnuclear 
supematants, we found that EGF also selectively increased the 
intracellular levels of MRP and MEP, while platelet TGF-6 decreased them 
(Fig. IB). 
The intracellular and secreted levels of immunoprecipitated MRP 
and MEP rose and fell in parallel in response to EGF and platelet TGF-6. 
EGF increased intracellular and secreted levels of MRP and MEP by 2 to 
3-fold, while platelet TGF-6 decreased them by 2 to 4-fold compared with 
the control (Table 1). In most experiments, the decrease in secreted 
and intracellular levels of [^^S]methionine labeled MEP due to platelet 
TGF-6 was less than for MRP. 
Platelet TGF-6, GI/TGF-6, and EGF alone or combined had little or 
no effect on the total amount of [^^Sjmethionine incorporated into the 
detergent-soluble, cellular protein (postnuclear supernatant) fraction 
(Table 1). Hence, the effects of platelet TGF-6, GI/TGF-6 and EGF were 
specific for MRP and MEP. Also, the pattern of major [^^S]methionine-
labeled intracellular proteins were not affected by EGF or TGF-6 (Fig. 
2). 
Figure 1. The effect of growth regulators on the [^®S]methionine-labeled proteins 
secreted by Swiss 3T3 cells. The cells were plated in DME with 10% calf serum 
and grown until they were confluent. Then the medium was changed to fresh DME 
containing 2% calf serum for 2 days. Eighteen hours after the growth regulators 
were added to the conditioned medium, the cells were labeled with 
[^^S]methionine for 4 h. The secreted proteins in the medium (A), and 
intracellular MRP and HEP immunoprecipitated from the NP-40 soluble cell 
fraction (B) were resolved by SDS polyacrylamide gel electrophoresis as 
described in Materials and Methods. Fluorograms are shown. Additions to the 
cells were C, no addition; E, 10 ng/ml EGFf T3, 5 ng/ml platelet TGF-B; GI, 1.1 
unit/ml GI/TGF-B; and ET3, 10 ng/ml EGF plus 5 ng/ml platelet TGF-e. The 
positions of MRP and MEP are Indicated by the arrows. NRbS; normal rabbit 
serum, aMRP; immunoprecipitated with anti-MRP antiserum, oMEP; 
immunoprecipitated with antl-MEP antiserum 
1 
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Figure 1 (Continued) 
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Table 1. Effect of EGF, TGF-Ô» and Gl/TGF-3 on the levels of secreted and 
intracellular MRP and MEP 
Area under the protein peak normalized counts per minute® 
to intracellular acid-insoluble 
[^®S]rnethionine radioactivity 
(Fold over Control)^ 
Intracellular [^H]thymidine 
Secreted Protein Intracellular Protein Acid-insoluble 
[^®S]methionine 
Incorporation 
Addition MRP MEP MRP MEP Radioactivity 
Control 1.0 1.0 1.0 1.0 168607+3877 669±4 
EGF 2.6 1.9 2.1 1.7 169279+7641 1796±51 
Platelet TGF-e 0.3 0.5 0.5 0.7 171939±4826 552+36 
GI/TGF-B 0.5 0.3 0.3 0.5 140287+6951 793+117 
EGF + 1.6 1.2 1.0 1.3 160068+11701 1671+236 
Platelet TGF-B 
^Swiss 3T3 cells were grown as described for Fig. 1. The cells were incubated 
for 17 h with the additions listed and then labeled with [^®S]methionine or 
[^H]thymidine. The amount of acid-insoluble [^®S]methionine and [^H]thymidine 
incorporated by the cells was measured as described in Materials and Methods. 
^The secreted and intracellular MRP and HEP were immunoprecipitated by anti-MRP 
and anti-MEP antiserum, respectively. The areas under each peak of 
immunoprecipitated secreted and intracellular MRP and HEP were determined by 
scanning the fluorograms with a densitometer. The value of each area was normalized 
to the total amount of [^®S]methionine incorporated into the cells in each sample. 
Secreted and Intracellular proteins are expressed as a ratio of the control value. 
Each value is the average of 2 or 3 experiments. For each experiment the data 
points were the average of two independent estimates. The average of coefficients 
of variation in these experiments varied between 15.8% to 26.1%. 
Figure 2. The effect of growth regulators on the incorporation of 
[^^S]methionine into intracellular and nuclear proteins of 
Swiss 3T3 cells. 3T3 cells were cultured and labeled with 
[^^S]methionine as described for Fig. 1. The cells were 
lysed and separated into nuclear and postnuclear 
supematants, then both fractions were analyzed by 
electrophoresis. Additions to the cells were same as 
described for Fig. 1 
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Inhibition by platelet TGF-B of MRP and MEP synthesis was not 
accompanied by a similar inhibition of DNA synthesis. Whereas EGF-
stimulated [^Hjthymidine incorporation by about 3-fold, platelet TGF-B 
and GI/TGF-6 did not change the rate of DNA synthesis compared with the 
control (Table 1). 
To determine whether the inhibitory effect of platelet TGF-B on the 
induction of secreted proteins by growth factors was specific for 3T3 
cells, we tested another cell line derived from a different species. 
Human fibroblasts secrete a protein of % 52,000 that we have called 
Mitogen-Induced Protein (MIP52) (Chiang et al. manuscript in 
preparation). The secreted level of MIP 52 was stimulated by EGF about 
2-fold and was reduced by platelet TGF-B by 5-fold (Fig. 3). Platelet 
TGF-B also selectively increased the secreted level of a protein of 
48,000. 
Figure 3. Effect of EGF, platelet TGF-6, and their combination on the 
labeling of secreted protein by human fibroblasts. The human 
fibroblasts were cultured as described in Materials and 
Methods. They were labeled with [^®S]methionine for 4 h 
after a 24-h period of incubation with C, no addition; E, 10 
ng/ml EGF; TS, 5 ng/ml platelet TGF-g; and ETIS, 10 ng/ml EGF 
plus 5 ng/ml platelet TGF-6. The position of MIP 52 is 
indicated by the arrow 
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DISCUSSION 
In this report," we showed that platelet TGF-B reduced secreted and 
intracellular levels of MRP and MEP in Swiss 3T3 cells, whereas EGF 
increased their levels. The inhibition or stimulation of MRP and MEP 
synthesis by platelet TGF-B and EGF are selective effects. The levels 
of other secreted and the major intracellular proteins are unaffected 
and platelet TGF-B and EGF have no appreciable effect on the overall 
rate of protein synthesis. GI/TGF-6, which was purified from 
conditioned medium of BSC-1 cells, also selectively reduced the 
synthesis and secretion of MRP and MEP by Swiss 3T3 cells (Figs. 1 and 
2). Platelet TGF-B and GI/TGF-B have been shown to be functionally and 
structurally related proteins (22). 
Platelet TGF-B has been reported to increase (34), decrease (35), 
or have a biphasic effects (36) on the binding of EGF to cell surface 
receptors of NRK cells. It also has been shown that the effect of TGF-B 
on EGF-stimulated thymidine incorporation is directly related to its 
effect on EGF binding (36). If platelet TGF-B decreased MRP and MEP 
production by decreasing the number of EGF receptors or by blocking the 
initial stimulatory signals of EGF in Swiss 3T3 cells, we would expect 
TGF-B to also decrease the rate of EGF-stimulated [^H]thymidine and 
[^^S]methionine incorporation. As shown in Table 1, both [^H]thymidine 
and [^®S]methionine incorporation into acid-insoluble material were not 
reduced by platelet TGF-6 alone or with EGF. We also looked for a 
delayed effect of GI/TGF-B on DNA synthesis as reported in AKR-2B cells 
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(37). [^H]thymidine incorporation was measured at 5 h intervals over a 
period covering 10-50 h after the addition of GI/TGF-B, EGF, or GI/TGF-S 
plus EGF. There was no significant delayed mitogenic effect nor 
inhibitory effect of GI/TGF-6 on [^H]thymidine incorporation in Swiss 
3T3 cells (data not shown). Thus our results suggest that the 
inhibitory effect of platelet TGF-B on the production of intracellular 
as well as secreted MRP and MEP is not due to an effect of platelet TGF-
6 on the number of EGF receptors. 
Murine 3T3 cells are fibroblast-like cells from the embryo of 
Swiss/Webster mice (38). It was of interest to know whether GI/TGF-6 
and platelet TGF-B have similar effects on the production of EGF-
induced, secreted proteins in cells from another species. Here, we 
showed that platelet TGF-6 also inhibited the production of MIP 52 
induced by EGF in human fibroblasts. Thus platelet TGF-B acts 
antagonistically to EGF in both murine 3T3 cells and human fibroblasts. 
TGF-B also independently induces a 48,000 Mj. protein in human 
fibroblasts. 
As for other biological systems in which hormones regulate gene 
expression, there is a positive and a negative hormonal regulator. In 
this report, we have shown that platelet TGF-B acts oppositely to EGF in 
the induction of secreted proteins in monolayer cultures of fibroblasts 
of two species. In contrast to these observations, it has been reported 
that platelet TGF-B or GI/TGF-B interact synergistically with EGF or 
TGF-a in wound healing and collagen synthesis (4, 39), and in the 
secretion of inhibitor-inducible protein 48 (IIP48, Mp 48,000) by CCL-64 
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cells (Thalacker and Nilsen-Hamilton, manuscript in preparation). 
Our results show that platelet TGF-6 selectively regulates the 
expression of MRP, HEP, and MIP 52 through a mechanism that does not 
affect the overall rate of DNA synthesis. It has also been shown that 
the induction of c-myc by PDGF can be dissociated from the effect of 
PDGF on DNA synthesis (40). Thus it appears that growth factors 
stimulate two independent sets of events; one set that leads to an 
increase in DNA synthesis and the other that results in a selective 
increase in the production of certain proteins some of which are 
secreted. GI/TGF-B is capable of regulating one of the two pathways 
independently of the other. 
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SECTION II: 
TGF-e INHIBITS THE PRODUCTION OF A PROLACTIN-LIKE SECRETED 
PROTEIN (MRP) BY DECREASING THE LEVEL OF ITS mRNA 
Chiang, C-P.^, Hamilton, R. T.^, Nilsen-Hamilton, 
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Ames, Iowa 50011 
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ABSTRACT 
Mitogen-Regulated Protein (MRP) is a 34 kDa glycoprotein that has 
32% amino acid sequence homology with prolactin. Major Excreted Protein 
(MEP) is a 39 kDa glycosylated thiol protease that is secreted and also 
found in the lysosoraes. The production of MRP and MEP in Swiss 3T3 
cells is regulated by epidermal growth factor (EGF) and the BSC-1 growth 
inhibitor (GI/TGF-B) which is a transforming growth factor type 6. EGF 
increased whereas GI/TGF-B decreased the amount of [^^S]raethionine-
labeled MRP and MEP produced by 3T3 cells. TPA mimicked the effect of 
EGF and selectively increased the production of secreted and 
intracellular MRP and MEP. The lysosomotropic agent, ammonium chloride, 
and a protease inhibitor, leupeptin, increased the amount of MRP and MEP 
produced by 3T3 cells presumably because they inhibit the degradation of 
these protein by the lysosomal proteases. EGF stimulated the production 
of MRP and MEP equally well in both quiescent and growing cells whereas 
inhibition by GI/TGF-B depended on the growth state of the cells. 
GI/TGF-B had a much greater inhibitory effect on the induction of MRP by 
EGF in quiescent cells than growing cells. Similarly, the induction of 
MRP by TPA was reduced by GI/TGF-B in quiescent cells whereas it was not 
affected by GI/TGF-6 in growing cells. GI/TGF-B inhibited the 
production of MRP by quiescent cells equally well in the presence or 
absence of ammonium chloride and/or leupeptin. Thus GI/TGF-B did not 
regulate the levels of MRP by altering the rate of protein degradation. 
The changes in the amount of [^^S]methionine-labeled intracellular and 
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secreted MRP produced in response to treatment by EGF and GI/TGF-B were 
paralleled by similar changes in the level of MRP mRNA in growing and 
quiescent cells. Thus the major effect of GI/TGF-B is to regulate the 
level of MRP mRNA. These results also show that the amount of MRP and 
MEIP produced by 3T3 cells is a function of both the growth regulators 
that are present and the cell density or the growth state of the cells. 
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INTRODUCTION 
Type e transforming growth factor (TGF-6) is a small protein that 
reversibly induces nonneoplastic cells to grow independently of 
anchorage (1-4). TGF-6 from human platelet and GI/TGF-B from the 
conditioned medium of BSC-1 African green monkey kidney epithelial cells 
are closely related and are probably the same molecule (5). The effects 
of TGF-6 on different cell types varies. TGF-6 accelerates wound 
healing in rats (4). It acts synergistically with PDGF to stimulate 
colony formation in NRK cells, inhibits anchorage-dependent growth of 
NRK cells (6), stimulates DNA synthesis by AKR-2B cells after a 
prolonged prereplicative interval (7), and inhibits DNA synthesis in 
cells such as CCL64 and BSC-1 cells (5, 8, Thalacker and Nilsen-
Hamilton, manuscript submitted). 
The tumor promotor; 12-0-tetradecanoylphorbol-13-acetate (TPA), and 
growth factors; epidermal growth factor (EGF) and fibroblast growth 
factor (FGF), all selectively increase the levels of several secreted 
proteins by fibroblasts and epithelial cell lines from human, monkey, 
rat, and mouse (9, 10, Fienup et al., manuscript submitted, Thalacker 
and Nilsen-Hamilton, manuscript submitted, Chiang et al., manuscript in 
preparation). In Swiss mouse 3T3 cells, Mitogen-Regulated Protein (MRP) 
and Major Excreted Protein (MEP) are two major secreted proteins that 
are selectively induced by these growth regulators. MRP (Mj;- 34,000) is 
a heterogeneously glycosylated protein that is related in amino acid 
sequence to mammalian prolactin (11, 12). MRP is identical to 
proliferin discovered fay Linzer and Nathans (11, 12). HEP (Mj- 39,000) 
is a thiol protease that is both secreted and is also located 
intracellularly in the lysosomes (13). 
We have reported that platelet TGF-6 and GI/TGF-6 selectively 
decrease the amount of MRP and MEP synthesized by EGF-stimulated 
quiescent Swiss 3T3 cells (14). This effect on MRP and MEP synthesis 
was seen as a decrease in the amount of [^®S]methionine-lafaeled MRP and 
MEP secreted by the cells and found in the cells after a short (4 h) 
incubation with [^®S]methionine. 
We have found that the major effect of GI/TGF-6 in regulating the 
amount of MRP produced by 3T3 cells is to decrease the level of MRP 
mRNA. The decrease on the MRP mRNA level due to GI/TGF-6 is greater in 
quiescent cells than in growing cells. In quiescent cells, GI/TGF-6 
also significantly inhibits the production of MRP in cells stimulated by 
EGF or TPA or in the presence of inhibitors of protein degradation such 
as leupeptin and ammonium chloride. Thus GI/TGF-6 decreases the rate of 
production of MRP and MEP by regulating the levels of their mRNA rather 
than by regulating the rate of degradation or secretion of the proteins. 
The ability of GI/TGF-6 to decrease the levels of MRP mRNA is influenced 
by either the growth state of the cells or by cell density. 
MATERIALS AND METHODS 
Murine EGF was purchased from Collaborative Research. The BSC-1 
growth inhibitor (GI/TGF-B) was a gift from Robert W. Holley (Salk 
Institute, San Diego, Ch.). TPA was purchased from Sigma. Crystalline 
bovine insulin was obtained from Eli Lilly. PLF-I cDNA was a gift from 
Daniel Nathans (Johns Hopkins Univ., Baltimore, MD). [^^S]methionine 
(1195-1500 Ci/mmole), [^H]thymidine (51 Ci/mmole), and [a-^^P]dCTP (10 
mCi/ml) were purchased from Amersham-Searle. The [^^S]methionine was 
stored in liquid nitrogen until used. 
The EGF stocks were dissolved in 0.5% BSA, GI/TGF-B in 0.5 M acetic 
acid, and TPA in DMSO. Therefore as well as the additions indicated for 
each experiment, all treatments including the controls included 0.005% 
BSA and 1.7 mM acetic acid. When TPA was one of the additions in the 
experiment 0.1% DMSO was also present throughout. We have determined 
that at these concentrations BSA, acetic acid and DMSO do not affect the 
DNA synthesis or protein synthesis and secretion. 
Cell Culture and [^®S]methionine Labeling 
Stock cultures of murine swiss 3T3 cells were grown in Dulbecco-
Vogt's modified Eagle's medium (DME) supplemented with 10% calf serum 
and maintained at 37°C in a water-saturated atmosphere of 13% CO2, 87% 
air. For experiments with growing cells, cells were plated at a density 
of approximately 1.0 x lO'* cells/cm^ on multiwell plastic dishes with 
DME containing 10% calf serum and the experiments were started 2-3 days 
41 
later when the cells had reached 50% confluency. For experiments with 
quiescent cells, the cells were plated in DUE with 10% calf serum and 
grown until they were confluent. Then the medium was changed to fresh 
DME containing 2% calf serum for 2-3 days. Sixteen to eighteen hours 
after the appropriate additions were made, the cells were labeled with 
[SSgjmethionine for 4 h as described previously (9). 
SDS Polyacrylamide Gel Electrophoresis and Fluororadiography 
The samples of medium and nuclei containing [^^S]methionine-
labeled proteins were diluted with concentrated electrophoresis sample 
buffer to give a final concentration of 2% (w/v) SDS, 2% (v/v) 6-
mercaptoethanol, 10% glycerol, 0.004% bromophenol blue, and 59 mM Tris-
POw, pH 6.9. The samples were heated at 98°C for 2 min and then were 
resolved by SDS polyacrylamide gel electrophoresis. Fluorograms of PPO-
impregnated SDS polyacrylamide gels were scanned with a densitometer to 
determine the amount of [^^S]methionine incorporated into particular 
proteins. 
Immunoprecipitation Assay 
NP-40-soluble cell fraction or medium from [^^S]methionine-labeled 
cells were immunoprecipitated with anti-MRP and anti-MEP antisera using 
a final concentration of 1% of either antiserum. After preadsorption 
with 1% normal rabbit serum and 6.7 wg/ul killed Staphylococcus aureus, 
the antiserum and samples were incubated at 4°C for 2 h with 10.3 ug/ul 
killed S. aureus and immunoprecipitation buffer (0.15 M NaCl, 0.1% SDS, 
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1% NP40, 1% sodium deoxycholate, and 10 mM NaPi, pH 7.2). 
Inununoprecipitates were collected by centrifugation and washed three 
times with immunoprecipitation buffer. The samples were resuspended in 
electrophoresis sample buffer and then resolved by SDS polyacrylamide 
gel electrophoresis. 
Assay for Protein Synthesis 
The amount of [^^S]methionine incorporated into cellular proteins 
was determined by precipitating 5 yl samples of the NP40-soluble cell 
fraction with trichloroacetic acid (TCA). After a 30 min incubation 
with 10% TCA at 4°C, the precipitates were trapped on glass fiber 
filters and washed with 15 ml cold 10% TCA followed by 2 ml 95% ethanol. 
The amount of acid insoluble cpm in each sample was measured using a 
liquid scintillation spectrometer. 
Assay for DNA synthesis 
Incorporation of [^H]thymidine into cells grown on glass or plastic 
coverslips was measured as described by Nilsen-Hamilton et al. (9). 
Preparation of Cytoplasmic RNA 
In the same experiment in which the cells were assayed for 
[^^S]methionine labeling and [^H]thymidine incorporation, some cells 
plated in 15 cm culture dishes were used to determine the MRP mRNA 
levels. The preparation of cytoplasmic RNA was done as described by 
White and Bancroft (15). In brief, 50 ul of 20 ml trypsinized cells 
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were removed and made to 9.4% formaldehyde for the cell counts and the 
rest of the cells (3-13 x 10® cells/sample) were collected by 
centrifugation at 600 x g for 5 min. The cell pellet was resuspended in 
1.0 ml of phosphate-buffered saline (0.14 M NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO1,, and 8.1 mM NaaHPO»», pH 7.2) and again collected by 
centrifugation at 15,000 x g for 12 sec in sterile eppendorf tubes. 
After resuspending the pellet in 45 ul of ice-cold 1 mM EDTA, 10 mM 
mixed vanadyl ribonucleosides, 10 mM Tris, pH 7.0, the cells were lysed 
by two sequential additions of 5 nl of 5% NP-40 with a 5 min incubation 
on ice after each addition. The proteins were removed by two sequential 
phenol/chloroform extractions yielding cytoplasmic RNA samples each in 
100 ul. The cytoplasmic RNA sample (100 ul) was diluted 1:1 (v/v) with 
0.09 M NaCl, 0.009 M trisodium citrate and 14.8% formaldehyde. The 
sample was incubated at 60°C for 25 min, and then stored at -70°C until 
it was to be blotted onto nitrocellulose paper. 
Slot Blotting and Hybridization 
For blotting, 20-100 ul aliquots of each sample were serially 
diluted with 20 X SSC (0.15 M NaCl/0.015 M trisodium citrate) to produce 
samples of 200 wl. The diluted samples were applied individually with 
suction through a slot onto a soaked nitrocellulose paper using a 
Minifold II slot blotter (Schleicher & Schuell). The nitrocellulose 
paper was baked at 80°C in vacuo for 1 h. After prehybridization at 
42°C for 20 h, the cytoplasmic macromolecules on the nitrocellulose 
paper were hybridized with nick-translated ^^P-labeled PLF-I cDNA probe 
at 42°C for 48 h with constant shaking. The nitrocellulose paper was 
then washed 4 times at room temperature and 2 times at 65°C for 15 m in 
each and dried. The paper was exposed to film and the quantitative data 
obtained by scanning the area under the peak. The areas under each peak 
were normalized to cell number. 
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RESULTS 
The Elffect of GI/TGF-B and EGF on the Production of MRP and MRP 
Secreted by Growing and Quiescent Cells 
EGF stimulated and GI/TGF-B decreased the amount of 
C^®S]methionine-labeled MRP and MEP produced by both quiescent and 
growing cells (Fig. 1). The pattern of proteins secreted by quiescent 
and growing 3T3 cells and the effects of EGF and GI/TGF-B on the 
secretion patterns are shown in Fig. 1. The patterns for quiescent and 
growing cells were different, especially in the region of high molecular 
weight proteins. 
We used anti-MRP or anti-MEP antiserum to specifically precipitate 
the MRP or MEP from samples of medium and NP-40 soluble cell fraction. 
In both quiescent and growing 3T3 cells, the levels of secreted MRP and 
MEP were increased by EGF and decreased by GI/TGF-B (Fig. 2). However, 
the inhibitory effect of GI/TGF-B on the production of MRP by EGF-
stimulated cells was much less in growing cells than that in quiescent 
cells. 
The Effect of GI/TGF-B and EGF on the Levels of Intracellular 
MRP and MEP Produced by Quiescent and Growing Cells 
We also examined the effect of EGF and GI/TGF-B on the 
intracellular levels of MRP and MEP (Table 1) and compared these results 
with their effects on the secreted levels of MEP and MRP. EGF increased 
whereas GI/TGF-B decreased the levels of intracellular MRP and MEP in 
Figure 1. The secretion pattern of [^^S]niethionine-labeled proteins 
from quiescent and growing 3T3 cells. Swiss 3T3 cells were 
plated in DME with 10% calf serum at a density of 
approximately 1.0 x 10*' cells/cm^. For experiments with 
growing cells, the additions were made 2-3 days later. For 
experiments with quiescent cells, the cells were grown until 
they reached confluency, then the medium was changed to fresh 
DME containing 2% calf serum and the cells were incubated for 
another 2-3 days. Sixteen to eighteen hours after the growth 
regulators were added to the cultures, the cells were labeled 
with [SSgjmethionine for 4 h. The secreted proteins in the 
medium were resolved by SDS polyacrylamide gel 
electrophoresis as described in Materials and Methods. A 
fluorogram is shown. Additions to the cells were C, no 
addition; E, 10 ng/ml EGF; GI, 1.1 unit/ml GI/TGF-g; E+GI, 10 
ng/ml plus 1.1 unit/ml GI/TGF-6 
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Figure 2. Effect of EGF and GI/TGF-B on the amount of MRP and MEP secreted by quiescent 
and growing cells. Swiss 3T3 cells were cultured, treated, and labeled as 
described for Fig. 1. Immunoprecipitation and electrophoresis were done as 
described for Table 1. Additions to the cells were C, control? E, 10 ng/nil EGF; 
GI, 1.1 unit/ml GI/TGF-B; E+GI; 10 ng/nil EGF plus 1.1 unit/ml GI/TGF-6. Q, 
quiescent cells; G, growing cells 
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Table 1. Effect of EGF and GI/TGF-B on the levels of secreted and 
intracellular MRP and MEP produced by quiescent and growing 
Swiss 3T3 cellsS 
Area under the protein peak normalized 
to intracellular acid-insoluble 
[^®S]methionine radioactivity ^  
(Fold over Control)C 
Secreted Protein Intracellular Protein 
Addition MRP MEP MRP MEP 
QUIESCENT CELLS 
Control 1.0 1.0 1.0 1.0 
EGF 3.0***d 1.8*** 2.9** 1.7* 
GI/TGF-B 0.2**** 0.6**** 0.3**** 0.8 
EGF+GI/TGF-B 0.4**** 0.9**** 0.4**** 1.2* 
GROWING CELLS 
Control 1.0 1.0 1.0 1.0 
EGF 3.6*** 1.8* 2.0**** 1.2 
GI/TGF-6 0.5*** 0.4** 0.8 0.7 
EGF+GI/TGF-B 2.4 0.9** 1.2 1.0 
^Swiss 3T3 cells were grown as described for Fig. 1. The cells 
were incubated for 16-18 h with the additions listed and then labeled 
with [^^SJmethionine. 
^%ie amount of acid-insoluble [^^S]methionine incorporated by the 
cells was measured as described in Materials and Methods. 
^Secreted and intracellular MRP and MEP were immunoprecipitated 
from samples of medium and from samples of NP-40 soluble cellular 
fractions respectively using anti-MRP and anti-MEP antiserum. The areas 
under each peaks of immunoprecipitated MRP and MEP were determined by 
scanning the resulting fluorograms with a densitometer. The value of 
each area was normalized to the total TCA precipitable [^^S]methionine 
cpm in the sample. The amount of [^^S]methionine incorporated into 
secreted and intracellular proteins were expressed as ratios relative to 
the control value. 
^Each value is the average of 3-8 experiments with two independent 
estimates for each experiment. The paired Students t-test was used for 
statistical analysis. The analysis was done by comparing the values 
from control samples with the values from EGF- or GI/TGF-B-treated 
samples. The t-test for the EGF+GI/TGF-B-treated samples was done by 
comparing those samples with the EGF-treated samples. ****, p<0.001; 
***, p<0.005; **, p<0.01; *, p<0.05; where there are no asterisks the p 
value was >0.05. 
51 
quiescent cells. Although there was a significant decrease in the 
secreted levels of MRP and MEP in response to GI/TGF-6, the changes in 
the intracellular levels of MRP and MEP in growing cells due to GI/TGF-6 
were not statistically significant. 
Interaction of GI/TGF-6 with TPA, and the Effect of 
Leupeptin and Ammoniun Chloride on the Levels of Secreted MRP 
by Quiescent and Growing Cells 
TPA, leupeptin, and ammonium chloride also increased the amount of 
[^^S]methionine-labeled MRP and MEP in both quiescent and growing cells. 
GI/TGF-6 opposed the induction of MRP by TPA in quiescent cells whereas 
it had little or no effect on MRP production by growing cells (Fig. 3). 
The inhibitory effect of GI/TGF-6 on the production of MRP in quiescent 
cells was not altered by the presence of leupeptin and/or ammonium 
chloride. Similar results were found for intracellular MRP as for 
secreted MRP (data not shown). 
The Effect of GI/TGF-6 and EGF on the Level of MRP mRNA in 
Quiescent and Growing Swiss 3T3 Cells 
GI/TGF-6 decreased the level of MRP mRNA (Fig. 4). Again, as for 
the effects of GI/TGF-6 on the amount of MRP produced by the cells, the 
effect of GI/TGF-6 was much greater in quiescent cells than in growing 
cells. The increase in the level of MRP mRNA that occured in response 
to EGF was greater in quiescent cells than in growing cells whereas the 
increase in synthesis of MRP and MEP due to EGF was independent of 
Figure 3. Interaction of GI/TGF-B with TPA, and the effect of leupeptin and NHi»Cl on the 
levels of MRP secreted by quiescent and growing Swiss 3T3 cells. Cells were 
cultured as described for Fig. 1, and were then incubated with growth 
regulators in the presence or absence of GI/TGF-B for 16-18 h. [^®S]methionine 
labeling, immunoprecipitation, and electrophoresis were done as described for 
Table 1. Additions to the cells were C, Control; TPA, 10 ng/ml TPA; LEU, 200 
pg/ml leupeptin? NH(,C1, 10 mM ammonium chloride; L+N, 200 yg/ml leupeptin plus 
10 mM ammonium chloride; GI, 1.1 unit/ml GI/TGF-6 
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Figure 4. Effect of EGF and GI/TGF-6 on the level of MRP mRNA in 
quiescent and growing swiss 3T3 cells. Cells were plated in 
15 cm plates and incubated with growth regulators for 16-18 h 
as described for Fig. 1. The cytoplasmic preparation, slot 
blotting, and hybridization were done as described in 
Materials and Methods. Q, quiescent cells; G, growing cells; 
C, control; E, 10 ng/ml EGF; I, 1.1 unit/ml; E+I, 10 ng/ml 
EGF plus 1.1 unit/ml GI/TGF-6. Dilutions of the original 
extracted cytoplasmic RNA preparations were: 1:2, 1:5, and 
1:10 
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growth state. 
In Figure 5, the results obtained for the effects of EGF and 
GI/TGF-6 on the level of MRP mRNA and on the rate of production of 
secreted and intracellular MRP in both quiescent and growing cells are 
compared. 
Figure 5. Comparison of the effect of EGF and GI/TGF-e on the level of 
MRP mRNA with their effects on production of secreted and 
intracellular MRP in quiescent and growing cells. Cells were 
cultured as described for Fig. 1. [^®S]methionine labeling, 
immunoprec ip itat ion, electrophoresis, cytoplasmic 
preparation, slot blotting, and hybridization were done as 
decribed for Table 1 and Fig. 3. Control, no addition; EGF, 
10 ng/ml EGF. The hatched bar presents addition without 
GI/TGF-6, the open bar presents addition with 1.1 unit/ml 
GI/TGF-B. The level of significance was estimated as 
described for Table 1 
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DISCUSSION 
EGF stimulated whereas GI/TGF-6 inhibited the production of 
secreted and intracellular MRP and MEP in both quiescent and growing 
cells. The rates of production of other secreted and intracellular 
proteins were not altered. Thus EGF and GI/TGF-6 selectively alter the 
production of MRP and MEP. 
EGF stiumlated the production of MRP and MEP equally well in both 
quiescent and growing cells. However, GI/TGF-6 had a much stronger 
inhibitory effect on the induction of MRP by EGF by quiescent cells than 
by growing cells. TPA also induces MRP and MEP in Swiss 3T3 cells. 
Similarly, GI/TGF-6 opposed the induction of MRP by TPA to a greater 
extent in quiescent cells than in growing cells. 
GI/TGF-6 exerted its inhibitory effect on MRP production equally 
well in the absence or presence of leupeptin and ammonium chloride. It 
has been shown that ammonium chloride, a lysosomotropic agent, and 
leupeptin, a protease inhibitor, increase the level of [^^S]methionine 
labeled MRP (10, Nilsen-Hamilton et al., manuscript submitted, 
departments of Biochemistry and Biophysics and Zoology, ISU). Although 
diverse in their effects on cellular metabolism, lysosomotropic agents 
and protease inhibitors are all known to inhibit protein degradation by 
lysosomal proteases (16, 17, 18, 19, 20, 21, 22, 23). Thus it has been 
postulated that the rate of degradation of newly-synthesized MRP and MEP 
in the lysosomes is an important influence determining the levels of MRP 
and MEP. Because leupeptin and ammonium chloride did not affect the 
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inhibition of GI/TGF-6 on MRP production. It is likely that GI/TGF-6 • 
does not regulate the production of MRP by altering protein degradation 
by lysosomal proteases. 
The major effect of GI/TGF-6 in regulating the level of MRP 
synthesis is to decrease the level of MRP mRNA in 3T3 cells. The 
changes in the amount of [^^S]methionine-labeled intracellular and 
secreted MRP due to treatment by EGF and GI/TGF-6 are paralleled by 
similar changes in the level of MRP mRNA. Again, as for the effects of 
GI/TGF-6 on protein synthesis, the effect of GI/TGF-6 on MRP mRNA levels 
was much greater in quiescent than in growing cells. 
EGF stimulated the production of secreted and intracellular MRP and 
MEP equally well in both quiescent and growing cells but the increase in 
the level of MRP mRNA in response to EGF was much larger in quiescent 
cells (7-fold) than in growing cells (2-fold). These results indicate 
that posttranscriptional and/or translational as well as transcriptional 
mechanisms are probably involved in the induction of MRP by EGF. 
It has been shown that the ability of growth factors and the tumor 
promoter, TPA, to induce MRP and MEP production is correlated with their 
ability to stimulate DNA synthesis in 3T3 cells and in their TPA-
resistant variants (9, Fienup et al., manuscript submitted). However, 
GI/TGF-6 decreased the production of MRP and MEP without reducing the 
rate of [^H]thymidine incorporation by the cells. Thus the decrease in 
the level of MRP mRNA in response to GI/TGF-6 is not due to a decrease 
in the rate of DNA synthesis. GI/TGF-6 might decrease the level of MRP 
mRNA by decreasing the rate of transcription of the gene coding for MRP 
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or by increasing the rate of degradation MRP mRNA. 
In this report, we show that the inhibition of MRP production by 
GI/TGF-6 is much less significant in growing cells than in quiescent 
cells. However, EGF stimulates the production of secreted and 
intracellular MRP and MEP equally well in both quiescent and growing 
cells. It has also been found that the induction of MRP and MEP by FGF 
varies as a function of cell density (Alvarez-Azaustre and Nilsen-
Hamilton, manuscript in preparation, department of Biochemistry and 
Biophysics, ISU). The induction of MRP and MEP by FGF decreases as the 
density of Swiss 3T3 cells increases. The opposite phenomenon was seen 
in the regulation of a 52,000 daltons Mitogen-Induced Protein (MIP52) 
secreted by human fibroblasts. The production of MIP52 is stimulated by 
FGF, EGF, TPA, and serum in quiescent cells whereas there is a much 
smaller increase in MIP52 production in response to FGF and EGF in 
growing cells (Chiang et al., manuscript in preparation). Thus the 
response of a particular cell type to a growth regulator in the 
production of secreted proteins depends on which growth regulators are 
present and on the cell density or the growth state of the cells. 
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SECTION III: 
TGF-B AND EGF HAVE OPPOSITE EFFECTS ON THE PRODUCTION OF A 
SECRETED 52,000 DML-TON PROTEIN AND OF PROCOLLAGENASE 
BY HUMAN FIBROBLASTS 
Chiang, C-P.^, Hamilton, R. T.^, Nilsen-Hamilton, M" 
Departments of Zoology^ and Biochemistry and Biophysics^ 
Iowa State University 
Ames, Iowa 50011 
65 
ABSTRACT 
Human skin fibroblasts secrete a protein of 52,000 that we have 
called Mitogen-Induced Protein (MIP52). The amount of [^^S]methionine-
labeled MIP52 secreted by quiescent human fibroblasts was selectively 
increased by FGF, EGF, TPA, and 10% calf serum. The extent to which 
FGF, EGF, and TPA induced the cells to produce MIP52 was variable. 
GI/TGF-B selectively opposed the induction of secreted MIP52 by EGF or 
TPA. There was no correlation between the production of MIP52 and the 
incorporation of [^H]thymidine stimulated by growth factors or TPA. The 
rate of production of [^^S]methionine-labeled MIP52 began to increase 
approximately 8 h after the addition of growth factors and reached a 
maximum at 20 to 24 h. The production of MIP52 by growth factors was 
inhibited by actinomycin D. This suggests that growth factors may 
induce MIP52 by increasing the rate of transcription of MIP52 mRNA. The 
increased production of MIP52 in response to EGF and FGF depends on the 
growth state of the cells or on the cell density. Quiescent cells 
responded much more vigorously to growth factors in producing MIP52 than 
did growing cells- The possibility that MIP52 is one of the proteases 
or protease inhibitors known to be secreted by human skin fibroblasts 
was tested. By immunoprecipitation, gel electrophoresis, and from tests 
for the ability to form a covalent complex with protease nexin, we found 
that MIP52 is not urokinase or its proenzyme, transin, protease nexin, 
or a serine protease. MIP52 is probably procoUagenase. It has many 
physical properties in common with procoUagenase. Also, we found that 
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treatment with GI/TGF-6 results in decreased trypsin-activated 
coUagenase activity as well as a decreased amount of MIP52 in the 
medium. Thus our results show that the production of MIP52 and the 
amount of coUagenase activity secreted into the medium are regulated 
positively by TPA and growth factors such as EGF and negatively by 
GI/TGF-6. GI/TGT-B selectively opposes the action of EGF and TPA on the 
production of MIP52 and coUagenase by a pathway that does not similarly 
affect the rate of DNA synthesis. 
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INTRODUCTION 
Growth factors such as platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF), and transforming growth factor-6 (TGF-B) 
selectively regulate the amount of certain proteins secreted by 
fibroblasts and epithelial cell lines of human, monkey, rat, and mouse 
origin (1, 2, 3, 4, 5, 6, 7, Thalacker and Nilsen-Hamilton, manuscript 
submitted, Chiang et al., manuscript in preparation)-
Recently, we reported that TGF-6 inhibited the production of 
secreted Mitogen-Induced Protein of 52,000 {MIP52) whereas it 
stimulated the production of another protein (Mp 48,000) by human skin 
fibroblasts (7). Human skin fibroblasts secrete a number of proteins 
including proteases and protease inhibitors such as collagenase (8, 9), 
urokinase proenzyme (10, 11), collagenase inhibitor (12, 13, 14), 
protease nexin (15, 16, 17), and transin (Matrisian et al., manuscript 
submitted). Transin is a secreted protease which shares approximately 
48% amino acid sequence homology to human skin collagenase (Matrisian et 
al., manuscript submitted, Strasbourg Cedex, France). The synthesis and 
secretion of transin and several other proteases and protease inhibitors 
by human skin fibroblasts have also been reported to be regulated fay 
growth factors, the tumor promoter; 12-0-tetradecanoylphorbol-13-actate 
(TPA), and glucocorticoids (12, 18, 19). 
Proteases and protease inhibitors are believed to play a crucial 
role in maintaining and restructuring the extracellular matrix 
architecture in cellular proliferation in vivo, tissue differentiation, 
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and tissue repair (20, 21, 22, 23). 
In this report, we tested the possibility that MIP52 is one of the 
proteases or protease inhibitors known to be secreted by human skin 
fibroblasts in response to growth factors. Although MIP52, urokinase 
proenzyme, protease nexin, and transin have similar molecular weights, 
we found that MIP52 was not recognized by anti-urokinase antiserum nor 
by two different anti-transin antisera. From the enzyme-inhibitor 
complex binding tests, MIP52 does not appear to be a serine protease nor 
a serine protease inhibitor with a mechanism of action similar to that 
of protease nexin. It is possible that MIP52 is procollagenase. MIP52 
and procollagenase have similar molecular weights, are induced by TPA 
and growth factors, and have the same time course of appearance after 
induction. 
We also studied the regulation of MIP52 production by different 
growth regulators. FGF, E6F, TPA, and calf serum selectively increased 
the production of MIP52 by human fibroblasts. Of the growth regulators 
tested, TPA is the most potent stimulator of MIP52 production. GI/TGF-B 
acted oppositely to the growth factors and TPA in regulating the 
secreted level of MIP52, decreasing the amount of MIP52 secreted by TPA 
or EGF-stimulated cells. The induction of MIP52 by growth regulators is 
growth state or cell density dependent. Much more MIP52 was produced in 
response to growth factors by quiescent cells than by growing cells. 
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MATERIALS AND METHODS 
FGF purified from bovine pituitary was a gift from Dr. D. 
Gospodarowicz (University of California, San Francisco, CA.). Murine 
EGF was purchased from Collaborative Research. The BSC-1 growth 
inhibitor (GI/TGF-g) was a gift from Robert W. Holley (Salk Institute, 
San Diego, CA.). Protease nexin and anti-urokinase antiserum were gifts 
from Dr. B. Baker (University of Kansas, Lawrence, KS.). Anti-transin 
antiserum and [^^S]methionine-labeled medium from B-77 cells were gifts 
from Dr. L. Matrisian (Strasbourg Cedex, France). TPA and gelatin was 
purchased from Sigma. Crystalline bovine insulin was obtained from Eli 
Lilly. Trypsin (L-l-tosylamino-2-phenylethly-chloromethylketone-
treated) and trypsin inhibitor (soybean) were purchased from Cappel 
Worthington. [^^S]methionine (1195-1500 Ci/mmole) and [^H]thyraidine (51 
Ci/mmole) were purchased from Amersham-Searle, The [^^S]methionine was 
stored in liquid nitrogen until used. 
Cell Culture 
Stock cultures of human fibroblasts were grown in Dulbecco-Vogt's 
modified Eagle's medium (DUE) supplemented with 10% or 20% fetal calf 
serum and maintained at 37°C in a water-saturated atmosphere of 13% CO?, 
87% air. 
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[^Sgjmethionine Labeling and 
SDS Polyacrylamide Gel Electrophoresis 
For experiments with growing cells, human fibroblasts were plated 
on multiwell plastic dishes and assayed three days later while they were 
still growing. For experiments with quiescent cells, the cells were, 
plated on DME with 10% fetal calf serum and grown until they were 
confluent, In some experiments, once the cells were confluent the 
medium was changed to DME containing 0.1% fetal calf serum and the cells 
were incubated for an additional 2-3 days before the experiment was 
started. The appropriate additions were made to the medium and the 
cells were incubated for an additional 24 or 48 h. The conditioned 
medium was then collected for the collagenase assay and for "substrate 
gels", and the cells were labeled with [^^S]methionine for 4 h as 
described previously (1). The medium containing [^^S]methionine labeled 
proteins was diluted with concentrated electrophoresis sample buffer to 
give a final concentration of 2% (w/v) SDS, 2% (v/v) g-mercaptoethanol, 
10% glycerol, 0.004% bromophenol blue, and 59 mM Tris-POi,, pH 6.9. 
Then they were resolved by SDS polyacrylamide gel electrophoresis. 
Fluorograms of PPO-impregnated SDS polyacrylamide gels were scanned with 
a densitometer to determine the amount of [^^S]methionine incorporated 
into particular proteins. 
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Assay for [^^S]methionine Incorporation 
The amount of [^^S]methionine incorporated into cellular proteins 
was determined by incubating 5 or 10 vl samples of the NP40-soluble cell 
fractions with cold 10% cold TCA for 30 min. The precipitates were 
trapped on glass fiber filters and washed with 15 ml cold 10% TCA 
followed by 2 ml 95% ethanol. The amount of incorporated into acid 
insoluble material was measured using a liquid scintillation 
spectrometer. 
Measurement of [^H]thymidine Incorporation 
Incorporation of [^Hjthyraidine into cells grown on glass or plastic 
coverslips was measured as described by Nilsen-Hamilton et al. (1). 
Immunoprecipitation Assay 
Samples of medium containing [^^Sjraethionine labeled proteins were 
immunoprecipitated with anti-prourokinase or two different anti-transin 
antisera. After preadsorption with normal rabbit serum and 6.7 yg/wl 
killed Staphylococcus aureus, the antiserum and samples were incubated 
at 4°C for 2 h with 10.3 yg/ul killed S. aureus and immunoprecipitation 
buffer (0.15 M NaCl, 0.1% SDS, 1% NP40, 1% sodium deoxycholate, and 10 
mM NaPi, pH 7.2). Immunoprecipitates were collected by centrifugation 
and washed three times with immunoprecipitation buffer. The samples 
were resuspended in electrophoresis sample buffer and then resolved by 
SDS polyacrylamide gel electrophoresis. 
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Test for the Formation of a Covalent Complex with Protease Nexin 
The incubation of medium from [^^S]methionine labeled cells with 
trypsin or/and protease nexin was done as described by Scott and Baker 
(16). The incubation of trypsin and protease nexin was done in the same 
time as the positive control. The samples were then resolved by SDS 
polyacrylamide gel electrophoresis under both reducing and nonreducing 
conditions. Gels were PPO-impregnated and exposed to film to produce 
fluorograms or stained with silver to detect the proteins directly. 
Assay for Collagenase Activity 
To determine collagenase activities in the medium, the medium from 
cells treated for 48 h with or without growth regulators was collected 
and precipitated with ammonium sulfate to 60% saturation. After 
centrifuging at 13,000 x g for 15 min, the pellets were resuspended in 
30 ul of buffer A (5 mM Tris-HCl, pH 7.5 and 1 mM CaClz) and dialyzed 
against two 1 liter changes of this buffer overnight. The collagenase 
assay was performed using a collagenase assay kit from New England 
Nuclear carried out according to the instructions included with the kit. 
[^H]collagen in buffer A was incubated at 4°C for 2 h to allow the 
formation of collagen fibrils. A portion of each concentrated dialyzed 
sample was activated by trypsin (0.167 jjg per 10 ul dialyzed sample) at 
room temperature for 30 min. The reaction was terminated by adding a 
10-fold excess of trypsin inhibitor. The activated samples were then 
added to the [^H]collagen fibrils and incubated at room temperature for 
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24 h in 100 yl reaction mixtures. After centrifuging at 13,000 x g for 
15 min, the amount of radioactivity released from type I [^H]collagen 
fibrils was measured by counting 85 yl the supernatant of the reaction 
mixture in a triton-toluene based scintillation fluid with a liquid 
scintillation spectrometer. 
A second portion of concentrated dialyzed conditioned medium was 
diluted in electrophoresis sample buffer and resolved by SDS 
polyacrylamide-substrate gel electrophoresis through a gradient (7.5%-
15%) polyacrylamide gel containing 1 mg/ml of type I gelatin. After 
electrophoresis, the gel was incubated with shaking in 2.5% Triton X-100 
for 1 h at room temperature with two changes. The gel was incubated at 
37°C for 48 h in buffer A with 0.02% NaNa to allow for digestion of 
gelatin by the collagenase. The gel was then fixed and stained in 
0.05% Coomassie Blue in 25% isopropanol and 10% acetic acid and 
destained in water. The quantitive analysis was done by scanning the 
area under the digested protein peaks using a densitometer. 
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RESULTS 
The Effects of FGF, TPA, EGF, and Calf Serum 
on the Production of MIP52 
Human skin fibroblasts secrete a protein of 52,000 that we have 
called Mitogen-Induced Protein (MIP52). The amount of [^^S]methionine-
labeled MIP52 secreted by quiescent human fibroblasts was selectively 
increased by FGF, EGF, TPA, and 10% calf serum. The extent to which 
FGF, EGF, and TPA induced the cells to produce MIP52 was variable. The 
amount of two other [^^S]methionine-labeled secreted proteins (M^-
180,000 and 32,000) were also slightly increased by these growth 
regulators (Fig. 1). The protein of 180,000 was shown to be collagen 
due to its sensitivity to degradation by purified collagenase (data not 
shown). 
Interaction of GI/TGF-B, EGF, and TPA in Their Effects on the 
Production of MIP52 by Human Skin Fibroblasts 
Results such as those shown in Fig. 1 were analyzed quantitatively 
by scanning the area under the protein peak and normalizing the area to 
the intracellular acid-insoluble C^^S]methionine radioactivity (Table 
1). The effect of EGF and TPA on the amount of MIP52 synthesized and 
secreted was selectively opposed by GI/TGF-6 (Table 1). 
Figure 1. Comparison of the effects of several growth regulators on the 
production of MIP52. Quiescent human fibroblasts were 
incubated for 24 h with 0.005% BSA and 0.1% DMSO in the 
absence or in the presence of either 100 ng/ml FGF, 10 ng/ml 
TPA, 10 ng/ml EGF, or 10% calf serum. The cells were then 
labeled for 4 h with [^^S]methionine and the proteins in the 
medium resolved by SDS polyacrylamide gel electrophoresis as 
described in Materials and Methods. A fluorogram of the gel 
is shown. The numbers on the left of the figure show the 
molecular weights of the proteins used as standards. The 
arrows point to three secreted proteins whose levels are 
regulated by growth factors. Their average molecular weights, 
estimated from this and other gels are 180,000, 52,000, and 
32,000. The 180,000 protein is collagen as is degraded by 
purified collagenase. Control (-); EGF (E); FGF (F); TPA (T); 
Serum (S) 
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Table 1. Interaction of GI/TGF-B, EGF, and TPA in their effects on 
the production of MIP52 by human fibroblasts^ 
counts per minute Area under the protein peak normalized 
to intracellular acid-insoluble 
Intracellular [^^S]methionine radioactivity 
Acid-insoluble (Fold over Control) 
[^^S]methionine 
Addition Radioactivity^ Secreted MIP52C 
Control 69153±3498 1.00 
GI/TGF-B 89081±1931 0.38 
EGF 81500±1130 2.16 
EGF+GI/TGF-B 96621±1163 0.94 
TPA 67194±2441 14.05 
TPA+GI/TGF-6 89587+5217 2.82 
^Quiescent human fibroblasts were incubated for 48 h with the 
indicated additions and then labeled with [^®S]metfaionine. 
^%ie amount of acid-insoluble [^^S]methionine incorporated by the 
cells was measured as described in Materials and Methods. 
^The area under each peak of secreted MIP52 was determined by 
scanning the fluorograms with a densitometer. The value of each area 
was normalized to the total amount of [^^S]methionine incorporated into 
the cells in each sample. The amount of [^^Slmethionine-labeled 
secreted MIP52 is expressed as a ratio of the control value. Each value 
is the average of 2 independent estimates. The average coefficient of 
variation in this experiment was 14.5%. 
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Time Course of the MIP52 Production in Response to FGF 
in Quiescent Cells 
The time course of the increase in MIP52 production after the 
addition of growth factor is relatively slow. The rate of production of 
[^^S]raethionine-labeled MIP52 began to increase approximately 8 h after 
the addition of growth factors and reached a maximum at 20 to 24 h (Fig. 
2). However the increased rate of production of MIP52 was very stable 
remaining elevated for at least 48 h after addition of the growth 
factors or TPA. 
Effect of Actinomycin D on the Production of MIPS2 
The production of MIP52 fay growth factors was inhibited by 
actinomycin D (Fig. 3). This suggests that growth factors may induce 
MIP52 by increasing the rate of transcription of MIP52 mRNA. Although 
the time course of its appearance is slow, the increase in the rate of 
production of MIP52 is probably a primary response to the growth 
regulators, involving no other protein synthesis. This was indicated by 
the observation that cycloheximide did not inhibit the increase in MIP52 
when it was added to cells at the same time as the growth factor and was 
removed immediately before labeling with [^^S]methionine for 4 h (data 
not shown).. 
Figure 2. Time course of the Increase in HIP52 production after the addition of FGF to 
quiescent human fibroblasts. Quiescent human fibroblasts were Incubated with 
FGF (100 ng/ml) for the times shown. They were then labeled with 
t^^S]methionine and the [^®S]methionine-labeled proteins secreted into the 
medium were resolved by SDS polyacryalmide gel electrophoresis. The amount of 
label incorporated into HIP52 was determined by scanning the band on 
fluorograms of gels. The figure shows the result of two separate experiments. 
In the first experiment (filled symbols) the cells were labeled with 
[^^S]methionine for 2 h, and in the second experiment (open symbols) the 
labeling period was 4 h. The values for both experiments were normalized to the 
area obtained for the 22 h point. The basal levels for the two experiments are 
different. This variation in the basal level was a consistent finding and was 
probably due to variation in the level of growth factor In the medium before 
FGF was added to the cells. • o, control with no FGF added; A A, with 100 ng/ml 
FGF; o A experiment 1; • A experiment 2 
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Figure 3. Effect of actinomycin D on the production of MIP52 by 
quiescent human fibroblasts. Quiescent human fibroblasts 
were incubated in the presence or absence of 100 ng/ml FGF. 
When FGF was added, 1 ug/ml actinomycin D was also added to 
some cells (Act D) and not to others (CONT). Twenty hours 
later the cells were labeled with [^^S]methionine and the 
proteins secreted into the medium were resolved by SOS 
polyacrylamide gel electrophoresis. In the fluorogram shown, 
the arrow points to MIP52. To the left of the figure the 
positions of the proteins used as molecular weight markers 
are shown by dots, and their molecular weights (in thousands) 
recorded beside the dot. F, FGF; -, no addition; CONT, no 
actinomycin D; ActD, with actinomycin D 
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A Comparison of the Elffects of TPA and Growth Factors on the 
Level of MIPS2 and on DNA Synthesis 
There was no correlation between the production of MIP52 and the 
incorporation of [^H]thymidine stimulated by growth factors or TPA (Fig. 
4). The effect of insulin on MIP52 production and [^H]thymidine 
incorporation depended on the cell strain and varied greatly. For most 
cell lines, the rate of MIP52 production was slightly inhibited or not 
affected after treatment with insulin whereas insulin slightly increased 
the rate of [^H]thymidine incorporation. We tested 27 human fibroblast 
strains each derived from a different individual. For most cell 
strains, TPA had slightly inhibitory or no effect on DNA synthesis. 
However, TPA is the best stimulator of MIP52 production. GI/TGF-6 had 
no effect on the incorporation of [^H]thymidine while it reduced the 
production of MIP52 2-4 fold (Fig. 4). 
A Comparison of the Effects of EGF and FGF on the Production of 
MIP52 by Quiescent and Growing Human Fibroblasts 
To determine whether the ability to produce MIP52 might depend on 
the growth state of the cells, we measured the effect of EGF and FGF on 
the production of secreted MIP52 in both quiescent and growing cells. 
Quiescent cells responded much more vigorously in producing MIP52 in 
response to growth factors than did growing cells (Fig. 5). 
Figure 4. A comparison of the effects of TPA and growth factors on the 
level of MIP52 and on DNA synthesis. Quiescent human 
fibroblasts were treated with growth factors or TPA for 24 h 
then labeled with [^^S]methionine or [^H]thymidine for 4 h. 
Control, no addition; EGF, 10 ng/ml; FGF, 100 ng/ml; Insulin, 
1 yg/ml; GI/TGF-B, 1.1 unit/ml; TPA, 10 ng/ml 
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Figure 5. A comparison of the effects of growth factors on the 
production of MIP52 by quiescent and growing human 
fibroblasts. Human fibroblasts were grown in DME with 10% 
fetal calf serum. While the cells were still growing, EGF 
or FGF was added and 24 h later the cells were labeled with 
[^^S]methionine in the presence and absence of growth 
factors. Other cells were allowed to reach confluency and 
were left for three days before EGF or FGF was added. These 
cells were also treated for 24 h with EGF or FGF and labeled 
for 4 h with [^^S]methionine. The amount of MIP52 was 
determined after scanning the area under MIP52 band on a 
fluorogram 
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Identification of MIP52 
Urokinase. Urokinase Proenzyme, Transin, and MIP52 
We tested MIP52 to determine whether it could be the urokinase or 
its proenzyme, or transin by immunoprecipitating with antisera specific 
for these proteins. MIP52 was not recognized by the anti-human 
urokinase antibody nor by two different anti-transin antisera (data not 
shown)• While one of the anti-transin antisera was able to precipitate 
a molecule immunologically related to transin from human fibroblast 
conditioned medium, this protein was not MIP52. 
Protease Nexin, Serine Protease, and MIP52 
Protease nexin covalently binds serine proteases. Formation of the 
complex result in an increase in the apparent M^s of protease nexin and 
the protease after electrophoresis through a nonreducing SDS 
polyacrylamide gel. To determine whether MIP52 was protease nexin or a 
serine protease, we incubated the [^^S]methionine-labeled medium with 
plasmin and/or protease nexin and resolved the samples by SDS 
polyacrylamide gel electrophoresis under reducing and nonreducing 
conditions (data not shown). MIP52 did not bind plasmin suggesting that 
MIP52 is not protease nexin. After incubation with protease nexin the 
apparent of MIP52 also did not change suggesting that MIP52 is not a 
serine protease. 
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Collaqenase and MIP52 
Because MIP52 and procollagenase have similar molecular weights and 
are both induced by TPA and growth factors (10 and Fig. 1), we suspected 
that MIP52 might be procollagenase. Collagenase migrates through SDS 
polyacrylamide gel electrophoresis with different mobilities when it is 
reduced compared with when it is not reduced (24). The apparent 
molecular weight of MIP52 was also different when MIP52 was resolved by 
SDS polyacrylamide gel electrophoresis under reducing or nonreducing 
condition (data not shown). We measured the amount of trypsin-activated 
collagenase activity in conditioned medium from cells incubated with or 
without TPA or GI/TGF-6. Collagenase activity was also measured after 
resolving samples of medium containing MIP52 by electrophoresis through 
SDS polyacrylamide gels containing gelatin. The collagenase activity 
measured using both of these assays was slightly increased by TPA (Table 
2). In the same experiment there was a large increase in the amount of 
[^^S]methionine-labeled MIP52 produced after TPA treatment (Table 2). 
GI/TGF-6 decreased both the amount of collagenase activity in the medium 
and the amount of MIP52 produced in response to TPA (Table 2). 
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Table 2. Effects of TPA and GI/TGF-6 on collagenase activity, 
collagenase production, and MIP52 production^ 
Addition 
Total 
Collagenase 
Activity^ 
52 kDa 
Collagenasec MIP52d 
Control l.OOe 1.00 1.00 
TPA 1.55 1.93 10.58 
GI/TGF-6 0.91 0.99 0.51 
TPA+GI/TGF-6 1.14 0.89 5.17 
^Human fibroblasts were grown in DME with 10% fetal calf serum 
until they were quiescent. Then the medium were changed to DME 
containing 0.1% fetal calf serum and the cells were incubated for an 
additional 2-3 days before the experiment was started. TPA or/and 
GI/TGF-6 was added to the cells and incubated for 45 h. 
^The conditioned medium was collected and assayed for collagenase 
activity as described in Materials and Methods. 
^The conditioned medium was resolved by SDS polyacrylamide gel 
gelectrophoresis through a gel containing 1 mg/ml of type I gelatin. 
After electrophoresis, the gel was incubated for 48 h to detect 
collagenase activity as described in Materials and Methods. 
•^The cells were labeled with [^^S]methionine for 4 h. 
[^^S]methionine labeled medium samples were resolved by SDS 
polyacrylamide gel electrophoresis. The gel was PFO-impregnated and 
exposed to film to produce a fluorogram. The fluorogram were scanned by 
a densitometer. 
®Each value is the average of 2 experiments with two independent 
estimates of each experiment. 
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DISCUSSION 
F6F, EGF, serum, and TPA selectively increased the amount of 
[^^S]methionine labeled MIP52 secreted by human fibroblasts. Serum has 
the largest stimulatory effect on DNA synthesis yet it stimulated the 
production of MIP52 much less effectively than did FGF, EGF, or TPA. 
This can be explained by our previous observation that platelet TGF-6 
reduces the amount of secreted MIP52 and opposes the effect of EGF in 
stimulating MIP52 production (7). Serum contains TGF-6 (25) and PDGF 
(26). PDGF acts similarly to EGF and FGF in Swiss 3T3 cells in 
stimulating MRP production and probably also stimulates MIP52 
production. Thus it is likely that serum contains both stimulatory and 
inhibitory factors that regulate the secreted levels of MIP52. 
As for the interaction between EGF and platelet TGF-6 or GI/TGF-6 
in regulating MIP52 production, the stimulation of MIP52 production by 
TPA was inhibited by GI/TGF-6. GI/TGF-6 did not reduce the overall rate 
of [^Sgjmethionine incorporated by the cells whereas it selectively 
decreased the production of secreted MIP52. The selective effects of 
EGF, FGF, TPA, and GI/TGF-6 were analyzed quantitively by scanning the 
area under the MIP52 band in fluorograms of gels and then normalizing 
the area to the amount of acid-insoluble [^^S]methionine radioactivity 
incorporated. We found that the effects of FGF, EGF, TPA, and GI/TGF-6 
in stimulating or inhibiting the production of MIP52 are selective for 
this protein. 
For the growth regulators tested, we found no correlation between 
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the ability to stimulate or inhibit MIP52 production and the ability to 
regulate DNA synthesis. For example, GI/TGF-B decreased secreted MIP52 
without inhibiting DNA synthesis and TPA stimulated the production of 
secreted MIP52 without increasing DNA synthesis- Thus the induction of 
MIP52 can be dissociated from the changes in DNA synthesis. Similarly, 
the induction of c-myc by PDGF and the inhibition of Mitogen-Regulated 
Protein (MRP) and Major Secreted Protein (MEP) synthesis by GI/TGF-B can 
be dissociated from the effect of these growth regulators on DNA 
synthesis (27, 7). Thus it seems that as well as regulating DNA 
synthesis, growth factors and GI/TGF-B independently regulate the 
expression of certain genes some of which code for secreted proteins. 
The extent of the increase in the production of secreted MIP52 in 
response to growth factors depended on growth state of the cells. The 
production of MIP52 stimulated by FGF and EGF was much greater in 
quiescent cells than for growing cells. A similar growth state 
dependence was observed in the mouse 3T3 fibroblasts in their ability to 
responsd to GI/TGF-B MRP production. GI/TGF-B is more effective in 
inhibiting MRP production in quiescent cells than in growing cells. EGF 
seems to stimulate the production of MRP and MEP equally well in both 
quiescent and growing Swiss 3T3 cells (Chiang et al., manuscript in 
preparation), whereas FGF (Alvarez-Azaustre and Nilsen-Hamilton, 
manuscript in preparation) and TPA (Fienup et al., manuscript submitted) 
was more effective in stimulating MRP production in growing cells. 
Transin (Mp 58,000-60,000) is a secreted protease that has 48% 
amino acid homology with human skin collagenase (Matrisian et al.. 
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manuscript submitted). The level of transin mRNA is increased by 
oncogenes and by EGF in rat embryo fibroblast cell lines (28). Trans in 
mRNA is also transiently increased by tumor promoting phorbol ester in 
normal epidermis. Two different anti-transin antisera were tested for 
their ability to immunoprecipitate [^®S]methionine-labeled MIP52. One 
of the anti-transin antisera was directed against a synthetic peptide 
corresponding to 23 amino acids of the deduced transin sequence and the 
other was directed against transin derived from gel slices containing 
trans in that had been produced in E. coll. The antiserum against the 
synthetic peptide did not precipitate MIP52 but instead specifically 
precipitated a protein with a higher molecular weight than MIP52. Thus, 
MIP52 is probably not transin. 
Urokinase proenzyme is secreted by human fibroblasts as a single 
chain 52,000 dalton protein that can be activated by plasmin, yielding 
an active two-chain urokinase of Mj. 33,000 and 19,000 dalton (11). We 
tested the possibility that MIP52 is urokinase or its proenzyme by 
attempting to immunoprecipitate MIP52 from [^^S]methionine-labeled 
medium using the anti-human urokinase antiserum. We also tried to 
cleave MIP52 into two 33 kDa and 19 kDa fragments with plasmin. MIP52 
was not recognized fay anti-urckinase antiserum nor was it cleaved by 
plasmin. These results suggested that MIP52 is not the urokinase or its 
proenzyme. 
Protease nexin (M^ 53,000) is a factor released by fibroblasts that 
forms SDS-stable complexes with urokinase, plasmin, trypsin, thrombin, 
and other serine proteases (15, 29, 30). The ability of MIP52 to form 
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an SDS-stable complex with protease nexin was tested to determine 
whether MIP52 could be a serine protease. MIP52 did not form a covalent 
complex with protease nexin suggesting that it is not a serine protease. 
MIP52, first treated with plasmin and then incubated with protease 
nexin, did not form a 78,000 dalton complex confirming that MIP52 is not 
the urokinase proenzyme. Also incubation of [^^S]methionine-lafaeled 
MIP52 with plasmin or trypsin did not change the apparent molecular 
weight of MIP52 from 52 kDa to the expected 120 kDa or 77 kDa of the 
complex suggesting that MIP52 is not protease nexin itself. 
The time course of MIP52 induction is similar to that reported for 
procollagenase production in response to growth factors in human 
fibroblasts. Both proteins begin to increase approximately 8-10 h after 
the addition of growth factors and reach a maximum at 20-26 h (Fig. 2 
and 18, 19). MIP52 has a similar molecular weight to procollagenase. 
Moreover, we found there was a difference in the apparent molecular 
weight of MIP52 when it was resolved by SDS polyacrylamide gel 
electrophoresis under reducing vs nonreducing conditions. Collagenase 
also travels with different mobilities when reduced compared with when 
it is unreduced. 
We compared the effect of TPA and GI/TGF-g on the collagenase 
activity in the medium of human fibroblasts with their effect on the 
production of [^^Sjmethionine-labeled MIP52. TPA stimulated the 
production of MIP52 11-fold whereas it only increased the collagenase 
activity approximately 1.6-fold. Similarly, there was only a small 
increase in collagenase activity assayed in the medium of TPA stimulated 
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cells after SDS gel electrophoresis. 
Chua et al. (ô) reported that TGF-B, EGF, and PDGF each stimulated 
human fibroblasts to produce collagenase. In contrast we found that 
5I/TGF-B decreased the production of secreted MIP52. On the other hand, 
human platelet TGF-6 and GI/TGF-6 did selectively increase the 
production of one 48 kDa protein in human skin fibroblasts (7). In some 
experiments, EGF also stimulated the production of this protein. The 
effect of TGF-B on collagenase activity was not reported by Chua et al. 
(6). Thus, it is possible that the 48 kDa protein was the one they 
observed in their gel system. 
In summary, we reported that GI/TGF-6 inhibits whereas EGF, FGF, 
and TPA stimulates the production of MIP52 secreted by human skin 
fibroblasts. GI/TGF-S is also capable of opposing the stimulation of 
MIP52 production due to EGF or TPA. MIP52 is probably procollagenase. 
The inhibition of MIP52 production by GI/TGF-g was not accompanied by 
inhibition of DNA synthesis. Thus GI/TGF-6 opposes the action of growth 
factors such as EGF and FGF on the production of secreted proteins by a 
pathway that does not affect the rate of initiation of DNA sythesis in 
fibroblasts from human skin as well as from mouse embryos. 
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DISCUSSION AND SUMMARY 
Transforming growth factors are a new class of growth regulator 
with diverse functions in regulating cell proliferation (75, 76, 81, 
82), nutrient transport (79, 80), wound healing (77, 78), and gene 
expression (82, 132, 133). Although TGFs are being studied extensively, 
the mechanisms by which these mitogens regulate cell growth are still 
not clear. In this thesis, the effects of human platelet TGF-6 and 
GI/TGF-B from BSC-1 cells on the production of secreted protein, their 
mRNA levels, and DNA synthesis were investigated in fibroblasts from two 
different species. The interaction of TGF-gs with EGF and TPA on the 
production of secreted proteins was also studied. 
TGF-gs decreased whereas EGF stimulated the production of MRP and 
MEP in murine 3T3 cells. The effect of human TGF-6 and GI/TGF-B on 
secreted and intracellular levels of MRP and MEP was dissociated from 
its effect on [^H]thymidine incorporated into the cells. The overall 
rate of [^H]thymidine as well as [^^Sjmethionine incorporation was not 
affected by human TGF-6 and GI/TGF-6. Growth factors increase the 
levels of MRP and MEP mRNA, thereby increasing the intracellular and 
secreted levels of these proteins (125, 129, 130, 131). I found GI/TGF-
6 decreased the amount of MRP mRNA in both quiescent and growing 3T3 
cells and inhibited the rise in MRP mRNA that occurred in response to 
EGF. Thus GI/TGF-6 reduces the production of MRP by decreasing the 
amount of its mRNA. 
The tumor promoter, TPA, mimics the effects of growth factors on 
the production of MRP and MEP (129, Fienup et al., manuscript 
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submitted). I showed that GI/TGF-S also opposes the effect of TPA on 
the production of secreted and intracellular MRP in quiescent cells. 
Thus, GI/TGF-6 interacts with growth factors and tumor promoter equally 
well in the regulation of MRP and MEP gene expression. 
Lysosomotropic agents and protease inhibitors are all known to 
inhibit protein degradation by lysosomal proteases (142, 143, 144, 145, 
146). Lysosomotropic agents such as ammonium chloride may also inhibit 
fusion of secretory granules with lysosomes (Nilsen-Hamilton et al., 
manuscript submitted). The rate of degradation of newly-synthesized MRP 
and MEP in the lysosomes is important in determining the level of MRP 
and MEP. Thus treatment with ammonium chloride results in a large 
increase in the secreted levels of MRP and MEP (118). The protease 
inhibitor, leupeptin, inhibits degradation of proteins by lysosomal 
proteases and thus causes a large buildup of intracellular MRP and MEP. 
In order to determine whether GI/TGF-6 decreases the amount of 
[^^S]methionine labeled MRP by selectively increasing the rate of MRP 
and MEP degradation, the effect of GI/TGF-6 on the production of MRP was 
compared in the presence and absence of leupeptin or ammonium chloride. 
GI/TGF-6 decreased MRP production equally well in the presence or 
absence of ammonium chloride and leupeptin. Thus GI/TGF-6 does not 
regulate MRP production by altering the rate of their protein 
degradation. 
The ability of GI/TGF-g to inhibit the production of MRP varied 
with the growth state of the cells. It has also been found that the 
induction of MRP by FGF and TPA is much greater in growing cells than in 
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quiescent cells (Fienup et al., manuscript in preparation), and that the 
ability of FGF to induce MRP and ME? is also density dependent (Alvarez-
Azaustre and Nilsen-Hamilton, manuscript in preparation). However, EGF 
stimulated the production of secreted and intracellular MRP and MEP 
equally well in both quiescent and growing cells. Thus the effects of 
growth factors and TPA on the production of MRP and MEP often depend on 
the cell density or growth state of the cells. 
There was a good correlation between the effects of growth factors 
on levels of MRP mRNA and their effects on production of MRP. Also, as 
seen for protein synthesis the extent of the decrease in the level of 
MRP mRNA in response to GI/TGF-g was much greater in the quiescent than 
in growing cells. 
A selective decrease in the production of a secreted proteins by 
TGF-Bs was also observed in human fibroblasts. MIP52 production was 
stimulated by calf serum, TPA, and growth factors such as FGF and EGF. 
Human TGF-6 and GI/TGF-g inhibited the production of secreted MIP52 
alone or in the presence of EGF or TPA. The stimulation of EGF and FGF 
of the production of secreted MIP52 was much greater in quiescent than 
in growing human skin fibroblasts. 
In order to identify the function of MIP52, we tested the 
possibility that MIP52 might be one of the proteins known to be secreted 
by human fibroblasts. Human skin fibroblasts secrete many proteins 
including proteases and protease inhibitors. Our results suggest that 
MIP52 is not a urokinase or its proenzyme, trans in, protease nexin, or 
serine protease. MIP52 has many properties in common with 
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procollagenase. The collagenase activity in the medium also decreased 
after treatment with GI/TGF-6. Therefore, MIP52 is probably 
procollagenase. 
In summary, I have shown that TGF-gs specifically inhibits the 
production of three different proteins secreted by fibroblasts from two 
different species. The production of all three of these proteins is 
also selectively stimulated by TPA and growth factors such as EGF and 
FGF. The major effect of GI/TGF-6 in regulating the level of MRP 
synthesis is to decrease the level of MRP mRNA in Swiss 3T3 cells 
whereas EGF increases the amount of MRP mRNA per cell. The growth state 
of the cells affected the ability of GI/TGF-6 to decrease the rate of 
MRP synthesis by Swiss 3T3 cells whereas this was not so for the 
stimulatory effects of the EGF. The ability of EGF and FGF to stimulate 
the production of secreted MIP52 also depended on the growth state of 
the human skin fibroblasts. 
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